FindTrial
Sign In

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01373736
Enrollment
Unknown
Registered
2011-06-15
Start date
Unknown
Completion date
Unknown
Last updated
2011-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoid Tumors, Medullary Thyroid Carcinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

Brief summary

The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.

Interventions

DRUG123I-meta-iodobenzylguanidine

Sponsors

Vancouver Coastal Health
Lead SponsorOTHER_GOV

Study design

Primary purpose
DIAGNOSTIC

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors; * subjects must be able and willing to comply with study procedures.

Exclusion criteria

* Subjects with history of renal insufficiency (serum creatinine level \> 3.0 mg/dL \[265 µmol/L\]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake; * Subjects unable to tolerate lying supine; * Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.

Countries

Canada

Contacts

Primary ContactDaniel Worsley, MD
worsley@triumf.ca604-875-4629

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026